Drugs / DF6215
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06108479 | Nov 2023 → Dec 2025 | cancer | Dragonfly Therapeutics | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-11-07 | Dragonfly Therapeutics | Results Dragonfly to Present Preclinical Data on Clinical-Stage DF6215, its Engineered IL-2R alpha-active Agonist, and DF9001, its EGFR-targeting TriNKET®, at SITC dragonflytx.com ↗
Data show that Dragonfly's DF6215 IL-2 cytokine drives greater therapeutic benefit in vivo than non-alpha IL-2, with no evidence of capillary leak syndrome or cytokine release syndrome . |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-11-07 | Dragonfly Therapeutics | Dragonfly to Present Preclinical Data on Clinical-Stage DF6215, its Engineered IL-2R alpha-active Agonist, and DF9001, its EGFR-targeting TriNKET®, at SITC dragonflytx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DF6215 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06108479 ↗ |
| Modality | Protein / enzyme biologic | “Immunotherapy (cytokine) targeting effector cells.” NCT06108479 ↗ |